52329-20-1 Usage
Uses
Used in Pharmaceutical Industry:
6-α-chloro-5-β-hydroxywithaferin A is used as a potential therapeutic agent for various health conditions due to its anti-cancer, anti-inflammatory, and neuroprotective properties. Its anticancer activity is attributed to its ability to induce apoptosis and inhibit tumor growth in various cancer cell lines. Additionally, it has shown potential for neuroprotective effects by reducing oxidative stress and inflammation in the brain.
Used in Cancer Research:
6-α-chloro-5-β-hydroxywithaferin A is used as a subject of research in cancer studies for its potential as an anticancer agent. It has demonstrated the ability to induce apoptosis and inhibit tumor growth, making it a promising candidate for further investigation and development in the field of oncology.
Used in Neuroprotective Applications:
6-α-chloro-5-β-hydroxywithaferin A is used as a neuroprotective agent for its potential to reduce oxidative stress and inflammation in the brain. This property makes it a candidate for the development of treatments for neurodegenerative diseases and conditions associated with cognitive decline.
Used in Anti-inflammatory Applications:
6-α-chloro-5-β-hydroxywithaferin A is used as an anti-inflammatory agent due to its potential to modulate inflammatory responses. This property can be beneficial in the development of treatments for inflammatory conditions and diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 52329-20-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,3,2 and 9 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 52329-20:
(7*5)+(6*2)+(5*3)+(4*2)+(3*9)+(2*2)+(1*0)=101
101 % 10 = 1
So 52329-20-1 is a valid CAS Registry Number.
52329-20-1Relevant academic research and scientific papers
Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers
Llanos, Gabriel G.,Araujo, Liliana M.,Jiménez, Ignacio A.,Moujir, Laila M.,Rodríguez, Jaime,Jiménez, Carlos,Bazzocchi, Isabel L.
supporting information, p. 52 - 64 (2017/09/20)
Apoptosis inducers represent an attractive approach for the discovery and development of anticancer agents. Herein, we report on the development by molecular fine tuning of a withaferin A-based library of 63 compounds (2–64), 53 of them reported for the first time. Their antiproliferative evaluation on HeLa, A-549 and MCF-7 human tumor cell lines identified fifteen analogues displaying higher activity (IC50 values ranging 0.3–4.8 μM) than the lead (IC50 values ranging 1.3–10.1 μM) either in lag or log growth phases. SAR analysis revealed that acylation enhances cytotoxicity, suggesting the hydrophobic moiety contributes to the activity, presumably by increasing affinity and/or cell membrane permeability. Further investigation clearly indicated that compounds 3, 11, 12, and 18 induce apoptosis evidenced by chromatin condensation, phosphatidylserine externalization, and caspase-3 activation effects on HeLa cells. The potent capacity to induce apoptosis with concomitant cell loss in G2/M highlights the potential of 27-benzyl analogue (18) as an apoptotic inducer drug candidate.
